Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2004 Feb;41(2):104–112. doi: 10.1136/jmg.2003.005033

The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease

J Lambert 1, N Coyle 1, C Lendon 1
PMCID: PMC1735679  PMID: 14757857

Abstract

Background: The ε4 allele of the apolipoprotein E (APOE) gene is a major genetic risk factor for Alzheimer's disease but appears to be associated with greater risk in women than in men. Some studies suggest that the level of APOE may of its own modulate the risk for Alzheimer's disease. Sex differences and an apparent benefit of oestrogen therapy suggest a role for oestrogen. APOE expression is influenced by oestrogen and oestrogen therapy may not benefit women bearing an APOE ε4 allele. These findings suggest an interaction between oestrogen and APOE in the Alzheimer's disease process.

Aim: To explore the hypothesis that APOE expression is regulated by a genomic mechanism and is modified by the polymorphisms in APOE associated with risk for Alzheimer's disease.

Methods: In vitro binding studies were undertaken between oestrogen receptors and fragments of the human APOE gene. APOE gene expression was studied to investigate a possible functional interaction.

Results: APOE ε2/ε3/ε4 coding and –219 G/T promoter polymorphisms influenced binding to the oestrogen receptor and altered transcriptional activity in response to oestrogen.

Conclusions: An allele dependent modulation of oestrogen induced regulation of APOE might be involved in the increased risk for Alzheimer's disease in women bearing an ε4 allele.

Full Text

The Full Text of this article is available as a PDF (491.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artiga M. J., Bullido M. J., Frank A., Sastre I., Recuero M., García M. A., Lendon C. L., Han S. W., Morris J. C., Vázquez J. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet. 1998 Nov;7(12):1887–1892. doi: 10.1093/hmg/7.12.1887. [DOI] [PubMed] [Google Scholar]
  2. Artiga M. J., Bullido M. J., Sastre I., Recuero M., García M. A., Aldudo J., Vázquez J., Valdivieso F. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 1998 Jan 9;421(2):105–108. doi: 10.1016/s0014-5793(97)01543-3. [DOI] [PubMed] [Google Scholar]
  3. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., Scarlato G., Amaducci L. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998 Apr;50(4):996–1002. doi: 10.1212/wnl.50.4.996. [DOI] [PubMed] [Google Scholar]
  4. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997 Nov;17(3):263–264. doi: 10.1038/ng1197-263. [DOI] [PubMed] [Google Scholar]
  5. Barrett-Connor E., Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993 May 26;269(20):2637–2641. [PubMed] [Google Scholar]
  6. Baum L., Chen L., Ng H. K., Pang C. P. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Microsc Res Tech. 2000 Aug 15;50(4):278–281. doi: 10.1002/1097-0029(20000815)50:4<278::AID-JEMT5>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  7. Behl Christian. Sex hormones, neuroprotection and cognition. Prog Brain Res. 2002;138:135–142. doi: 10.1016/S0079-6123(02)38075-0. [DOI] [PubMed] [Google Scholar]
  8. Berr C., Lambert J. C., Sazdovitch V., Amouyel P., Chartier-Harlin M. C., Mohr M., Heldt N., Kiesmann M., Hauw J. J. Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. Neurobiol Aging. 2001 Mar-Apr;22(2):227–235. doi: 10.1016/s0197-4580(00)00227-x. [DOI] [PubMed] [Google Scholar]
  9. Brandi M. L., Becherini L., Gennari L., Racchi M., Bianchetti A., Nacmias B., Sorbi S., Mecocci P., Senin U., Govoni S. Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. Biochem Biophys Res Commun. 1999 Nov 19;265(2):335–338. doi: 10.1006/bbrc.1999.1665. [DOI] [PubMed] [Google Scholar]
  10. Breitner J. C., Wyse B. W., Anthony J. C., Welsh-Bohmer K. A., Steffens D. C., Norton M. C., Tschanz J. T., Plassman B. L., Meyer M. R., Skoog I. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999 Jul 22;53(2):321–331. doi: 10.1212/wnl.53.2.321. [DOI] [PubMed] [Google Scholar]
  11. Bretsky P. M., Buckwalter J. G., Seeman T. E., Miller C. A., Poirier J., Schellenberg G. D., Finch C. E., Henderson V. W. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13(4):216–221. doi: 10.1097/00002093-199910000-00007. [DOI] [PubMed] [Google Scholar]
  12. Bullido M. J., Artiga M. J., Recuero M., Sastre I., García M. A., Aldudo J., Lendon C., Han S. W., Morris J. C., Frank A. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet. 1998 Jan;18(1):69–71. doi: 10.1038/ng0198-69. [DOI] [PubMed] [Google Scholar]
  13. Bullido M. J., Valdivieso F. Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease. Microsc Res Tech. 2000 Aug 15;50(4):261–267. doi: 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  14. Buttini M., Akeefe H., Lin C., Mahley R. W., Pitas R. E., Wyss-Coray T., Mucke L. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience. 2000;97(2):207–210. doi: 10.1016/s0306-4522(00)00069-5. [DOI] [PubMed] [Google Scholar]
  15. Coezy E., Borgna J. L., Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982 Jan;42(1):317–323. [PubMed] [Google Scholar]
  16. Costa M. M., Reus V. I., Wolkowitz O. M., Manfredi F., Lieberman M. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry. 1999 Jul 15;46(2):182–188. doi: 10.1016/s0006-3223(98)00355-2. [DOI] [PubMed] [Google Scholar]
  17. Driscoll M. D., Sathya G., Muyan M., Klinge C. M., Hilf R., Bambara R. A. Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem. 1998 Nov 6;273(45):29321–29330. doi: 10.1074/jbc.273.45.29321. [DOI] [PubMed] [Google Scholar]
  18. Fagan A. M., Holtzman D. M. Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. Microsc Res Tech. 2000 Aug 15;50(4):297–304. doi: 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  19. Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N., van Duijn C. M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997 Oct 22;278(16):1349–1356. [PubMed] [Google Scholar]
  20. Friedman G., Froom P., Sazbon L., Grinblatt I., Shochina M., Tsenter J., Babaey S., Yehuda B., Groswasser Z. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 1999 Jan 15;52(2):244–248. doi: 10.1212/wnl.52.2.244. [DOI] [PubMed] [Google Scholar]
  21. Geerlings M. I., Ruitenberg A., Witteman J. C., van Swieten J. C., Hofman A., van Duijn C. M., Breteler M. M., Launer L. J. Reproductive period and risk of dementia in postmenopausal women. JAMA. 2001 Mar 21;285(11):1475–1481. doi: 10.1001/jama.285.11.1475. [DOI] [PubMed] [Google Scholar]
  22. Growdon W. B., Cheung B. S., Hyman B. T., Rebeck G. W. Lack of allelic imbalance in APOE epsilon3/4 brain mRNA expression in Alzheimer's disease. Neurosci Lett. 1999 Sep 10;272(2):83–86. doi: 10.1016/s0304-3940(99)00557-1. [DOI] [PubMed] [Google Scholar]
  23. Guo Z., Cupples L. A., Kurz A., Auerbach S. H., Volicer L., Chui H., Green R. C., Sadovnick A. D., Duara R., DeCarli C. Head injury and the risk of AD in the MIRAGE study. Neurology. 2000 Mar 28;54(6):1316–1323. doi: 10.1212/wnl.54.6.1316. [DOI] [PubMed] [Google Scholar]
  24. Harwood D. G., Barker W. W., Loewenstein D. A., Ownby R. L., St George-Hyslop P., Mullan M., Duara R. A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics. Neurology. 1999 Feb;52(3):551–556. doi: 10.1212/wnl.52.3.551. [DOI] [PubMed] [Google Scholar]
  25. Henderson V. W., Paganini-Hill A., Miller B. L., Elble R. J., Reyes P. F., Shoupe D., McCleary C. A., Klein R. A., Hake A. M., Farlow M. R. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000 Jan 25;54(2):295–301. doi: 10.1212/wnl.54.2.295. [DOI] [PubMed] [Google Scholar]
  26. Holtzman D. M., Fagan A. M., Mackey B., Tenkova T., Sartorius L., Paul S. M., Bales K., Ashe K. H., Irizarry M. C., Hyman B. T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000 Jun;47(6):739–747. [PubMed] [Google Scholar]
  27. Houlden H., Crook R., Backhovens H., Prihar G., Baker M., Hutton M., Rossor M., Martin J. J., Van Broeckhoven C., Hardy J. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. Am J Med Genet. 1998 Feb 7;81(1):117–121. doi: 10.1002/(sici)1096-8628(19980207)81:1<117::aid-ajmg19>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  28. Inestrosa N. C., Marzolo M. P., Bonnefont A. B. Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiol. 1998 Winter;17(1-3):73–86. doi: 10.1007/BF02802025. [DOI] [PubMed] [Google Scholar]
  29. Jacobs D. M., Tang M. X., Stern Y., Sano M., Marder K., Bell K. L., Schofield P., Dooneief G., Gurland B., Mayeux R. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998 Feb;50(2):368–373. doi: 10.1212/wnl.50.2.368. [DOI] [PubMed] [Google Scholar]
  30. Jeltsch J. M., Roberts M., Schatz C., Garnier J. M., Brown A. M., Chambon P. Structure of the human oestrogen-responsive gene pS2. Nucleic Acids Res. 1987 Feb 25;15(4):1401–1414. doi: 10.1093/nar/15.4.1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Jones P. S., Parrott E., White I. N. Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent. J Biol Chem. 1999 Nov 5;274(45):32008–32014. doi: 10.1074/jbc.274.45.32008. [DOI] [PubMed] [Google Scholar]
  32. Jordan B. D., Relkin N. R., Ravdin L. D., Jacobs A. R., Bennett A., Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA. 1997 Jul 9;278(2):136–140. [PubMed] [Google Scholar]
  33. Kawas C., Resnick S., Morrison A., Brookmeyer R., Corrada M., Zonderman A., Bacal C., Lingle D. D., Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997 Jun;48(6):1517–1521. doi: 10.1212/wnl.48.6.1517. [DOI] [PubMed] [Google Scholar]
  34. Klinge C. M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001 Jul 15;29(14):2905–2919. doi: 10.1093/nar/29.14.2905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lambert J-C, Araria-Goumidi L., Myllykangas L., Ellis C., Wang J. C., Bullido M. J., Harris J. M., Artiga M. J., Hernandez D., Kwon J. M. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology. 2002 Jul 9;59(1):59–66. doi: 10.1212/wnl.59.1.59. [DOI] [PubMed] [Google Scholar]
  36. Lambert J. C., Berr C., Pasquier F., Delacourte A., Frigard B., Cottel D., Pérez-Tur J., Mouroux V., Mohr M., Cécyre D. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet. 1998 Sep;7(9):1511–1516. doi: 10.1093/hmg/7.9.1511. [DOI] [PubMed] [Google Scholar]
  37. Lambert J. C., Harris J. M., Mann D., Lemmon H., Coates J., Cumming A., St-Clair D., Lendon C. Are the estrogen receptors involved in Alzheimer's disease? Neurosci Lett. 2001 Jun 29;306(3):193–197. doi: 10.1016/s0304-3940(01)01806-7. [DOI] [PubMed] [Google Scholar]
  38. Lambert J. C., Mann D., Goumidi L., Harris J., Amouyel P., Iwatsubo T., Lendon C., Chartier-Harlin M. C. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet. 2001 Feb 24;357(9256):608–609. doi: 10.1016/S0140-6736(00)04063-0. [DOI] [PubMed] [Google Scholar]
  39. Lambert J. C., Pasquier F., Cottel D., Frigard B., Amouyel P., Chartier-Harlin M. C. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet. 1998 Mar;7(3):533–540. doi: 10.1093/hmg/7.3.533. [DOI] [PubMed] [Google Scholar]
  40. Lambert J. C., Pérez-Tur J., Dupire M. J., Galasko D., Mann D., Amouyel P., Hardy J., Delacourte A., Chartier-Harlin M. C. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet. 1997 Nov;6(12):2151–2154. doi: 10.1093/hmg/6.12.2151. [DOI] [PubMed] [Google Scholar]
  41. Laskowitz D. T., Horsburgh K., Roses A. D. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab. 1998 May;18(5):465–471. doi: 10.1097/00004647-199805000-00001. [DOI] [PubMed] [Google Scholar]
  42. Laws S. M., Hone E., Taddei K., Harper C., Dean B., McClean C., Masters C., Lautenschlager N., Gandy S. E., Martins R. N. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry. 2002;7(8):886–890. doi: 10.1038/sj.mp.4001097. [DOI] [PubMed] [Google Scholar]
  43. Laws Simon M., Hone Eugene, Gandy Sam, Martins Ralph N. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003 Mar;84(6):1215–1236. doi: 10.1046/j.1471-4159.2003.01615.x. [DOI] [PubMed] [Google Scholar]
  44. Lendon C. L., Harris J. M., Pritchard A. L., Nicoll J. A. R., Teasdale G. M., Murray G. Genetic variation of the APOE promoter and outcome after head injury. Neurology. 2003 Sep 9;61(5):683–685. doi: 10.1212/01.wnl.0000078033.81925.80. [DOI] [PubMed] [Google Scholar]
  45. Lendon C. L., Martinez A., Behrens I. M., Kosik K. S., Madrigal L., Norton J., Neuman R., Myers A., Busfield F., Wragg M. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mutat. 1997;10(3):186–195. doi: 10.1002/(SICI)1098-1004(1997)10:3<186::AID-HUMU2>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  46. Leslie K. K., Keefe D., Powell S., Naftolin F. Estrogen receptors are identified in the glioblastoma cell line U138MG. J Soc Gynecol Investig. 1994 Jul-Sep;1(3):238–244. doi: 10.1177/107155769400100311. [DOI] [PubMed] [Google Scholar]
  47. Lynch J. R., Morgan D., Mance J., Matthew W. D., Laskowitz D. T. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol. 2001 Mar 1;114(1-2):107–113. doi: 10.1016/s0165-5728(00)00459-8. [DOI] [PubMed] [Google Scholar]
  48. Maruyama H., Toji H., Harrington C. R., Sasaki K., Izumi Y., Ohnuma T., Arai H., Yasuda M., Tanaka C., Emson P. C. Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease. Arch Neurol. 2000 Feb;57(2):236–240. doi: 10.1001/archneur.57.2.236. [DOI] [PubMed] [Google Scholar]
  49. McEwen Bruce. Estrogen actions throughout the brain. Recent Prog Horm Res. 2002;57:357–384. doi: 10.1210/rp.57.1.357. [DOI] [PubMed] [Google Scholar]
  50. Miyata M., Smith J. D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 Sep;14(1):55–61. doi: 10.1038/ng0996-55. [DOI] [PubMed] [Google Scholar]
  51. Ophir Gal, Meilin Sigal, Efrati Margalit, Chapman Joab, Karussis Dimitri, Roses Allen, Michaelson Daniel M. Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. Neurobiol Dis. 2003 Feb;12(1):56–64. doi: 10.1016/s0969-9961(02)00005-0. [DOI] [PubMed] [Google Scholar]
  52. Paganini-Hill A., Henderson V. W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994 Aug 1;140(3):256–261. doi: 10.1093/oxfordjournals.aje.a117244. [DOI] [PubMed] [Google Scholar]
  53. Payami H., Zareparsi S., Montee K. R., Sexton G. J., Kaye J. A., Bird T. D., Yu C. E., Wijsman E. M., Heston L. L., Litt M. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet. 1996 Apr;58(4):803–811. [PMC free article] [PubMed] [Google Scholar]
  54. Petz L. N., Nardulli A. M. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol. 2000 Jul;14(7):972–985. doi: 10.1210/mend.14.7.0493. [DOI] [PubMed] [Google Scholar]
  55. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R. E., Mahley R. W., Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10914–10919. doi: 10.1073/pnas.95.18.10914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Roberts G. W., Allsop D., Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry. 1990 May;53(5):373–378. doi: 10.1136/jnnp.53.5.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Sabo T., Lomnitski L., Nyska A., Beni S., Maronpot R. R., Shohami E., Roses A. D., Michaelson D. M. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience. 2000;101(4):879–884. doi: 10.1016/s0306-4522(00)00438-3. [DOI] [PubMed] [Google Scholar]
  58. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001;62:231–252. doi: 10.1016/s0083-6729(01)62006-5. [DOI] [PubMed] [Google Scholar]
  59. Sathya G., Li W., Klinge C. M., Anolik J. H., Hilf R., Bambara R. A. Effects of multiple estrogen responsive elements, their spacing, and location on estrogen response of reporter genes. Mol Endocrinol. 1997 Dec;11(13):1994–2003. doi: 10.1210/mend.11.13.0039. [DOI] [PubMed] [Google Scholar]
  60. Seshadri S., Zornberg G. L., Derby L. E., Myers M. W., Jick H., Drachman D. A. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001 Mar;58(3):435–440. doi: 10.1001/archneur.58.3.435. [DOI] [PubMed] [Google Scholar]
  61. Sheng H., Laskowitz D. T., Bennett E., Schmechel D. E., Bart R. D., Saunders A. M., Pearlstein R. D., Roses A. D., Warner D. S. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab. 1998 Apr;18(4):361–366. doi: 10.1097/00004647-199804000-00003. [DOI] [PubMed] [Google Scholar]
  62. Sherwin Barbara B. Estrogen and cognitive functioning in women. Endocr Rev. 2003 Apr;24(2):133–151. doi: 10.1210/er.2001-0016. [DOI] [PubMed] [Google Scholar]
  63. Shumaker Sally A., Legault Claudine, Rapp Stephen R., Thal Leon, Wallace Robert B., Ockene Judith K., Hendrix Susan L., Jones Beverly N., 3rd, Assaf Annlouise R., Jackson Rebecca D. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28;289(20):2651–2662. doi: 10.1001/jama.289.20.2651. [DOI] [PubMed] [Google Scholar]
  64. Srivastava R. A., Srivastava N., Averna M., Lin R. C., Korach K. S., Lubahn D. B., Schonfeld G. Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor alpha-mediated pathway. J Biol Chem. 1997 Dec 26;272(52):33360–33366. doi: 10.1074/jbc.272.52.33360. [DOI] [PubMed] [Google Scholar]
  65. Steffens D. C., Norton M. C., Plassman B. L., Tschanz J. T., Wyse B. W., Welsh-Bohmer K. A., Anthony J. C., Breitner J. C. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J Am Geriatr Soc. 1999 Oct;47(10):1171–1175. doi: 10.1111/j.1532-5415.1999.tb05195.x. [DOI] [PubMed] [Google Scholar]
  66. Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Finch C. E. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci. 1998 May 1;18(9):3180–3185. doi: 10.1523/JNEUROSCI.18-09-03180.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Hajian H., Finch C. E. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol. 1997 Feb;143(2):313–318. doi: 10.1006/exnr.1996.6360. [DOI] [PubMed] [Google Scholar]
  68. Sun Y., Wu S., Bu G., Onifade M. K., Patel S. N., LaDu M. J., Fagan A. M., Holtzman D. M. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 1998 May 1;18(9):3261–3272. doi: 10.1523/JNEUROSCI.18-09-03261.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Szklo M., Cerhan J., Diez-Roux A. V., Chambless L., Cooper L., Folsom A. R., Fried L. P., Knopman D., Nieto F. J. Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1996 Dec 1;144(11):1048–1057. doi: 10.1093/oxfordjournals.aje.a008877. [DOI] [PubMed] [Google Scholar]
  70. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996 Aug 17;348(9025):429–432. doi: 10.1016/S0140-6736(96)03356-9. [DOI] [PubMed] [Google Scholar]
  71. Teasdale G. M., Nicoll J. A., Murray G., Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997 Oct 11;350(9084):1069–1071. doi: 10.1016/S0140-6736(97)04318-3. [DOI] [PubMed] [Google Scholar]
  72. Tolar M., Marques M. A., Harmony J. A., Crutcher K. A. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci. 1997 Aug 1;17(15):5678–5686. doi: 10.1523/JNEUROSCI.17-15-05678.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Town T., Paris D., Fallin D., Duara R., Barker W., Gold M., Crawford F., Mullan M. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998 Aug 14;252(2):95–98. doi: 10.1016/s0304-3940(98)00567-9. [DOI] [PubMed] [Google Scholar]
  74. Wakeling A. E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867–3873. [PubMed] [Google Scholar]
  75. Wang J. C., Kwon J. M., Shah P., Morris J. C., Goate A. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. Neurology. 2000 Dec 12;55(11):1644–1649. doi: 10.1212/wnl.55.11.1644. [DOI] [PubMed] [Google Scholar]
  76. Wang P. N., Liao S. Q., Liu R. S., Liu C. Y., Chao H. T., Lu S. R., Yu H. Y., Wang S. J., Liu H. C. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000 Jun 13;54(11):2061–2066. doi: 10.1212/wnl.54.11.2061. [DOI] [PubMed] [Google Scholar]
  77. Waring S. C., Rocca W. A., Petersen R. C., O'Brien P. C., Tangalos E. G., Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999 Mar 23;52(5):965–970. doi: 10.1212/wnl.52.5.965. [DOI] [PubMed] [Google Scholar]
  78. White F., Nicoll J. A., Roses A. D., Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis. 2001 Aug;8(4):611–625. doi: 10.1006/nbdi.2001.0401. [DOI] [PubMed] [Google Scholar]
  79. Xu P. T., Gilbert J. R., Qiu H. L., Ervin J., Rothrock-Christian T. R., Hulette C., Schmechel D. E. Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol. 1999 Feb;154(2):601–611. doi: 10.1016/S0002-9440(10)65305-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Yaffe K., Haan M., Byers A., Tangen C., Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000 May 23;54(10):1949–1954. doi: 10.1212/wnl.54.10.1949. [DOI] [PubMed] [Google Scholar]
  81. Yang D. S., Small D. H., Seydel U., Smith J. D., Hallmayer J., Gandy S. E., Martins R. N. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience. 1999;90(4):1217–1226. doi: 10.1016/s0306-4522(98)00561-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES